GlassScriptPhysician profile
Holly D Edmonds
NPI 1326244831
$9,984.35
in general payments reported to CMS, 2019-2025
36 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $289 · 2021: $1,360 · 2022: $1,912 · 2023: $2,089 · 2024: $1,943 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,686 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,686.40 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,807.07 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Genzyme Corporation | $1,036.99 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $832.31 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $828.83 | 2019-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $697.08 | 2019-2025 | Winlevi |
| Galderma Laboratories, L.P. | $532.20 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Leo Pharma INC. | $436.29 | 2019-2025 | Adbry |
| Amgen INC. | $383.80 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $374.00 | 2023-2024 | Sotyktu |
| Incyte Corporation | $365.40 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $352.83 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $314.44 | 2024-2025 | Zoryve |
| Almirall LLC | $273.22 | 2021-2025 | Seysara |
| Pfizer INC. | $250.94 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $245.48 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $198.63 | 2020-2025 | |
| Dermavant Sciences, INC. | $183.79 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $143.22 | 2021 | |
| Sandoz INC. | $88.40 | 2019-2020 | |
| Ucb, INC. | $78.37 | 2022-2024 | Cimzia, Bimzelx |
| Celgene Corporation | $68.57 | 2019 | |
| Allergan, INC. | $66.69 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $56.41 | 2023-2025 | Ycanth |
| Botanix Sb INC | $55.65 | 2025 | Sofdra |
| Organon LLC | $44.95 | 2024-2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.55 | 2019-2024 | Jublia |
| Nabriva Therapeutics, Plc | $35.55 | 2021-2022 | |
| Epi Health, LLC | $33.62 | 2021 | |
| Dermira, INC. | $25.39 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.08 | 2023 | Spevigo |
| Journey Medical Corporation | $20.00 | 2022 | |
| Fresenius Kabi USA, LLC | $18.49 | 2023 | Idacio |
| Kyowa Kirin, INC. | $16.34 | 2021 | |
| Merck Sharp & Dohme LLC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Edmonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.